latest news in companies
Netflix Breaks Tradition with Performance Bonuses for Affleck and Damon’s ‘The Rip’
Los Angeles, Saturday, 10 January 2026.
In a significant departure from its standard upfront payment model, Netflix has agreed to performance-based bonuses for all 1,200 crew members of the upcoming film “The Rip.” This strategic pivot, negotiated by Ben Affleck and Matt Damon, aligns compensation directly with viewership success.
Jim Cramer Rejects Nike Downgrade as Insider Buying Signals Turnaround
New York, Saturday, 10 January 2026.
CNBC’s Jim Cramer labeled a recent Nike downgrade “fatuous,” arguing that significant insider purchases by CEO Elliott Hill and Apple’s Tim Cook signal a genuine business turnaround despite analyst skepticism.
Johnson & Johnson Agrees to Lower Drug Prices in Exchange for Tariff Exemptions
New Brunswick, Saturday, 10 January 2026.
Securing crucial tariff exemptions, Johnson & Johnson agrees to slash U.S. drug prices to match international rates, becoming the latest industry giant to join the administration’s TrumpRx.gov initiative.
LuxUrban Report Separates Corporate Liabilities From Founder's Personal Finances
San Francisco, Sunday, 11 January 2026.
New filings argue LuxUrban’s financial collapse stems from systemic corporate risks, attempting to distinguish business exposure from the founder’s personal finances despite $98 million in guarantees.
Corcept Therapeutics Faces Market Selloff and Legal Probes Following FDA Rejection of Relacorilant
San Francisco, Friday, 9 January 2026.
Corcept Therapeutics (NASDAQ: CORT) is under intense pressure after the FDA issued a Complete Response Letter regarding its New Drug Application for relacorilant, a treatment for hypertension caused by hypercortisolism. The regulatory rejection, announced on December 31, 2025, precipitated a massive 50% collapse in share value, effectively erasing $3.6 billion in market capitalization. While the FDA acknowledged some positive trial data, it concluded that additional evidence is required to establish the drug’s effectiveness. Consequently, the company now faces a wave of investigations from shareholder rights law firms, including Hagens Berman and Scott+Scott. These inquiries focus on whether management overstated relacorilant’s clinical efficacy and the commercial prospects of its hypercortisolism business to investors. Analysts have subsequently downgraded price targets, casting doubt on Corcept’s ability to meet its projected revenue goals within the previously stated timeframe.
Apogee Enterprises Under Investigation After Stock Plunges Seventeen Percent
San Diego, Friday, 9 January 2026.
Apogee Enterprises faces a federal securities investigation after its stock plummeted 17% on January 7, 2026. The sharp decline coincided with missed revenue targets and the sudden resignation of CFO Matthew Osberg.